Синдром гиперандрогении у девочек пубертатного возраста

Автор: Арипова Фарида Собировна, Гайбуллаева Динара Фатхуллаевна, Карибаев Есгали Ергалиевич

Статья в выпуске: 2 (22), 2024 года.

Бесплатный доступ

Изучение синдрома пубертатной гиперандрогении может значительно расширить представления о патогенезе этого состояния и улучшить результаты лечения. Различные компоненты и симптомы повышенного уровня андрогенов могут появляться с течением времени и прогрессией заболевания. Все подростки с клиническими симптомами ГА должны динамически наблюдаться эндокринологом и гинекологом. Многофакторность данной патологии у пациенток репродуктивного возраста диктует необходимость изучения патогенеза заболевания у девочек в пубертатном возрасте, поскольку, в конечном итоге, это влияет на здоровье, качество жизни и психоэмоциональное состояние жещины.

Еще

Гиперандрогения, пубертатный период, синдром поликистозных яичников

Короткий адрес: https://sciup.org/14130756

IDR: 14130756

Список литературы Синдром гиперандрогении у девочек пубертатного возраста

Fauser B., Eijkemans M.J. Predicting pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:9:3183-3184.
Futterweit W., Nestler J., Reaven G. American Association of Clinical Endocrinologists. Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endor Pract 2005;11:2:126-- 134. mi
Ching H.L., Burke V., Stuckey B.G. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol 2007;66:3:373--379.
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.
Hum Reprod 2004; 19:1:41--47.Gilling-Smith C., Willis D.S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994;79:4:1158- 1165.
Kumar A., Woods K.S., Bartollucci A.A., Azziz R. Prevalence of adrenal androgen excess in patients with PCOS. Clin Endocrinol (Oxford) 2005;62:6:644-649.\
Mortensen M., Ehrmann D., Littlejohn E., Rosenfield R. L. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab2009;94:5:1579-1586.
Hirshfeld-Cytron J., Barnes R.B., Ehrmann D.A. et al. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:5:1587--1594.
Azziz R., Woods K.S., Reyna R. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin En-docrinol Metab 2004;89:6:2745- 2749.
Trakakis E., Basios G., Trompoukis P. et al. An update to 21-hy-droxylase deficient congenital adrenal hyperplasia. Gynecol En-docrinol 2010;26:1:63-71.
Zawadsky J.K., Dunaf A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach / Polycystic ovary syn-drome. Boston: Blackwell Scientific Publications 1992;377-384.
ESHRE/ASRM. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.Fertil Steril 2004;81:1:19--25.
Azziz R., Carmina E., Dewailly D. et al. The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete taskforse report. Fertil Steril 2009;91:2:456--488.
Ferriman D., Gallwey J.D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
Balen A., Laven J.S., Tan S. L., Dewailly D. Ultrasound assessment of polycystic ovary: international consensus definitions. Hum Re-prod Update 2003;9:6:505-514.
Escobar-Morreale H. E., Sanchon R., San Millan J. L. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008;93:2:527-533.
Unluhizarci K., Kula M., Dundar M. et al. The prevalence of non-classic adrenal hyperplasia among Turkish women with hyperan-drogenism. Gynecol Endocrinol 2010;26:2:139--143.
Kuttenn E, Coullin P., Giratd F. et al. Late-onset adrenal hyperplasia in hirsutism. N Engl J Med 1985;313:4:224-231.
Azziz R., Zacur HA. 21-Hydroxylase deficiency in female hyper-androgenism: screening and diagnosis. J Clin Endocrinol Metab1989;69:3:577-584.
Bider M., Bellanne-Chantelot C., Galand-Portier M.B. et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to
hydroxylase deficiency and 330 family members. J Clin Endo-crinol Metab 2009;94:5:1570-1578.
Lutfallah H., Wang W., Mason J.1. et al. Newly proposed hormonal criteria via genotypic proof for type I 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002;87:6:2611-2622.
Bhattacharya S. M. Metabolic syndrome in females with polycystic ovary syndrome and international Diabetes Federation criteria. J Obstet Gynaecol Res 2008;34:1:62-66.
Luque-Ramez M., Alvarez-Blasco E, Mendieta-Azcona C. et al.Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syn-drome. J Clin Endocrinol Metab 2007;92:6:2141--2148.
Deplewski D., Rosenfield R. Role of hormones in pilosebaceous unit development. Endor Rev 2000;21:4:363-392.
Ciaraldi T.P., Aroda V., Mudaliar S. et al. Polycystic ovary syndrome is associated with tissuespecific differences in insulin resistance. J Clin Endocrinol Metab 2009;94:1:157- 163.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endor Rev 1997;18:6:774-800.
Shah N.A., Antoine H.., Pall M. et al. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome.J Clin Endocrinol Metab 2008;93:5:1939-- 1945.
Панфилова Е.В. Гормональные, метаболические И молекулярно-генетические аспекты синдрома гиперандрогении у девочек. М 2006.
Paris E., Tardy V., Chalancon A. et al. Premature pubarche in Mediterranean girls: high prevalence of heterozygous CYP21 mutation carriers. Gynecol Endocrinol 2010;26:5:319-324.
Cho L. W., Kilpatrick E.S., Jauagopal V. et al. Biological variation of total testosterone, free androgen index and bioavailable testosterone Bider M., Bellanne-Chantelot C., Galand-Portier M.B. et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to
hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 2009;94:5:1570-1578.
Lutfallah H., Wang W., Mason J.1. et al. Newly proposed hormonal criteria via genotypic proof for type I 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002;87:6:2611-2622.
Bhattacharya S. M. Metabolic syndrome in females with polycystic ovary syndrome and international Diabetes Federation criteria. J Obstet Gynaecol Res 2008;34:1:62-66.
Luque-Ramez M., Alvarez-Blasco E, Mendieta-Azcona C. et al.
Obesity is the major determinant of the abnormalities in blood pressure found in young women with the polycystic ovary syn-drome. J Clin Endocrinol Metab 2007;92:6:2141--2148.
Deplewski D., Rosenfield R. Role of hormones in pilosebaceous unit development. Endor Rev 2000;21:4:363-392.
Ciaraldi T.P., Aroda V., Mudaliar S. et al. Polycystic ovary syndrome is associated with tissuespecific differences in insulin resistance. J Clin Endocrinol Metab 2009;94:1:157- 163.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endor Rev1997;18:6:774-800.
Shah N.A., Antoine H.., Pall M. et al. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome.J Clin Endocrinol Metab 2008;93:5:1939-- 1945.
Панфилова Е.В. Гормональные, метаболические и молекулярно-генетические аспекты синдрома гиперандрогении у девочек. М 2006.
Paris E., Tardy V., Chalancon A. et al. Premature pubarche in Mediterranean girls: high prevalence of heterozygous CYP21 mutation carriers. Gynecol Endocrinol 2010;26:5:319-324.
Cho L. W., Kilpatrick E.S., Jauagopal V. et al. Biological variation of total testosterone, free androgen index and bioavailable testosterone
in polycystic ovarian syndrome: implications for identifying hyperandrogenaemia. Clin Endocrinol (Oxford) 2008;68:3:390--394.
Stener-Victorin E., Holm G., Labrie F et al. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? J Clin Endocrinol Metab 2010;95:2:810-819.
Гончаров Н.П., Кация Г.В. Обзор литературы: Современные методы определения тестостерона. Вестн репрод здоровья2008;1-2:31-37.
Collignon I., Porquer D. Investigation of female reproductive hormone dysfunctions. Biomeieux. France. Lyon. Brochure. 2-18.
Ihanez L., Dimartino-Nardi J., Potau N., Saenger P. Premature adrenarche - normal variant or forerunner of adult disease? En-doer Rev 2000;21:6:671-696.
Rosenfield R.L. Clinical Review: Indentifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab.2007;92:3:787-796.
Penning T.M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endor Rev 2010; 18:3:281-305.
Петеркова В.А., Семичева Т.В. Диагностика и лечение синдрома гиперандрогении у девочек-подростков. М 2005.
Fleischman A., Gordon C. Adolescent menstrual abnormalities.
Pediatric Endocrinology 5’ Edition. Informa Healthcare. New York (USA) 2007;2:349-360.
Homburg R., Lambalk C.B. Polycystic ovary syndrome in adolescence - a therapeutic conundrum. Hum Reprod 2004; 19:5:1039-1042.
Pasquali R., Antenucci D., Casmirri E: Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. I Clin Endocrinol Metab 1989;68:173-179.

Еще

Статья научная